Recurrent Respiratory Papillomatosis

5

Review clinical trials related to Recurrent Respiratory Papillomatosis. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Merck IIT: RRP Pembro and Lenvatinib

This research study is studying Lenvatinib in combination with Pembrolizumab in people with human papillomavirus (HPV)-associated recurrent respiratory papillomatosis (RRP). The names of the study drugs involved in this study are: * Pembrolizumab * Lenvatinib

Participants needed: 20
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Yale UniversityUpdated: Jul 2, 2026Locations: 1
Eligibility criteria

For those patients with non-measurable pulmonary disease, participants must have... [+29]

Has received prior systemic anti-cancer therapy including investigational agents... [+27]

Status: Recruiting

Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients

The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients

Participants needed: 9
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Mayo ClinicUpdated: Apr 3, 2026Locations: 1
Eligibility criteria

Clinically confirmed diagnosis of recurrent respiratory papillomatosis. [+20]

Co-morbid systemic illnesses or other severe concurrent disease which, in the ju... [+9]

Status: Recruiting

Zopa Retreatment and Vector Shedding in Adults With RRP

This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, feces, skin, and nasal tissue; Cohort 2 to assess the complete response rate following retreatment.

Participants needed: 30
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Precigen, IncUpdated: Dec 15, 2025Locations: 3
Eligibility criteria

Age 18 years and older. [+7]

Conditions or therapies that increase risk or interfere with participation per i... [+6]

Status: Recruiting

The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)

Recurrent respiratory papillomatosis (RRP) is an orphan disease that affects approximately 20,000 people in the United States and is caused by infection with human papillomavirus (HPV) types 6 and 11. Since RRP is an orphan disease, it is an understudied disease entity with correspondingly few treatment options. The investigators hypothesize that by understanding the biology of RRP and the failed host immune responses against HPV, novel and rational therapies can be developed. This study will examine the genetic and immunologic alterations found in these rare tumors and distant metastatic involved sites (such as the lung) in patients diagnosed with RRP.

Participants needed: 100
Trial details
Age: 18-99Biological sex: AllType: ObservationalSponsor: Massachusetts General HospitalUpdated: Aug 12, 2025Locations: 1
Eligibility criteria

History of HPV-associated Recurrent Respiratory Papillomatosis [+1]

None

Status: Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

CoRDS, or the Coordination of Rare Diseases at Sanford, is based at Sanford Research in Sioux Falls, South Dakota. It provides researchers with a centralized, international patient registry for all rare diseases. This program allows patients and researchers to connect as easily as possible to help advance treatments and cures for rare diseases. The CoRDS team works with patient advocacy groups, individuals and researchers to help in the advancement of research in over 7,000 rare diseases. The registry is free for patients to enroll and researchers to access. Visit sanfordresearch.org/CoRDS to enroll.

Participants needed: 20,000
Trial details
Biological sex: AllType: ObservationalSponsor: Sanford HealthUpdated: May 29, 2025Locations: 2Duration: 100 Years
Eligibility criteria

Diagnosis of a rare disease, a disease of unknown prevalence, undiagnosed or an...

Diagnosis of a disease which is not rare